Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Taro Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT01769235
First received: January 14, 2013
Last updated: January 19, 2014
Last verified: January 2014
  Purpose

The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% and to demonstrate the superior efficacy of the two active formulations over that of the vehicle in the treatment of acne vulgaris.


Condition Intervention Phase
Acne Vulgaris
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Drug: Acanya® Gel, 1.2%/2.5%
Drug: Vehicle of test product
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Gel, 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Resource links provided by NLM:


Further study details as provided by Taro Pharmaceuticals USA:

Primary Outcome Measures:
  • Mean percent change in inflammatory lesion counts. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.

  • Mean percent change in non-inflammatory lesion counts. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Mean percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts.


Secondary Outcome Measures:
  • Clinical response of "success". [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The proportion of subjects at week 12 with a clinical response of "success" is defined as an Investigators Global Assessment score that is at least 2 grades less than the baseline assessment.


Enrollment: 1215
Study Start Date: November 2012
Study Completion Date: December 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Active Comparator: Acanya® Gel, 1.2%/2.5%
Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
Drug: Acanya® Gel, 1.2%/2.5%
Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
Placebo Comparator: Vehicle of test product
Vehicle of test product (Taro Pharmaceuticals Inc.)
Drug: Vehicle of test product
Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).

  Eligibility

Ages Eligible for Study:   12 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be willing and able to provide written informed consent/assent for the study.
  • Be 12 to 40 years of age, inclusive. A subject may be of either sex and any race/ethnicity.
  • Have a clinical diagnosis of facial acne vulgaris with 25 or greater non-inflammatory lesions and 20 or greater inflammatory lesions and no more than 2 nodulocystic lesions.
  • Have a baseline Investigator's Global Assessment of acne severity grade of 2, 3 or 4 on a severity scale of 0 to 4.
  • Be willing and able to understand and comply with the requirements of the study, apply the study medication as instructed, refrain from use of all other topical acne medication and topical antibiotics during the 12-week treatment period, return for the required treatment period visits, comply with therapy prohibitions, and able to complete the study.
  • Be in general good health and free from any clinically significant disease, other than acne vulgaris, that might interfere with the study evaluations.
  • Female subjects of childbearing potential must have a negative urine pregnancy test amd must be willing to use a medically accepted method of contraception during the study.

Exclusion Criteria:

  • Presence of more than 2 facial nodulocystic lesions (i.e., nodules and cysts).
  • Current diagnosis of acne conglobata, acne fulminans, or secondary acne.
  • Presence of active cystic acne, or polycystic ovarian syndrome.
  • History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis.
  • Presence of any other facial skin condition that might interfere with acne vulgaris diagnosis and/or assessment.
  • Excessive facial hair that would interfere with diagnosis or assessment of acne vulgaris.
  • History of unresponsiveness to topical clindamycin phosphate and/or benzoyl peroxide therapy.
  • Start or change of dose of estrogens or hormonal treatment 3 months prior to baseline or throughout the study.
  • Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days of study entry and throughout the study.
  • Use of any of the following treatments more recently than the indicated washout period prior to visit 1/day 1; need or intent to continue to use any of the following treatments during the study: oral retinoids or therapeutic Vitamin A supplements of greater than 10,000 units/day; systemic steroids; systemic antibiotics; systemic treatment for acne vulgaris ; systemic anti-inflammatory or immunosuppressive agents (NSAID use is allowed on an as-needed basis but for no more than 7 days of consecutive use, low dose aspirin is allowed if on a stable dose for at least 30 days); Spironolactone; use on the face of cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, x-ray therapy; topical retinoids; topical steroids; topical anti-acne medications; topical anti-inflammatory agents; topical antibiotics; medicated cleansers; use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun; antipruritics, including antihistamines.
  • History of hypersensitivity or allergy to clindamycin phosphate, benzoyl peroxide, and /or any ingredient in the study medication.
  • Females who are pregnant, breastfeeding, intending to become pregnant during the study, or who do not agree to use an acceptable form of birth control during the study.
  • Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise the subject's ability to comply with study requirements.
  • Any clinically significant condition or situation other than acne vulgaris that would interfere with the study evaluations or optimal participation.
  • Use of any investigational drugs within 30 days prior to visit 1/day 1.
  • Participation in any other clinical study in the 30 days prior to signing the informed consent form.
  • Previous participation in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Taro Pharmaceuticals USA
ClinicalTrials.gov Identifier: NCT01769235     History of Changes
Other Study ID Numbers: CLBG 1210
Study First Received: January 14, 2013
Last Updated: January 19, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Taro Pharmaceuticals USA:
Acne Vulgaris
Clindamycin Phosphate and Benzoyl Peroxide Gel
Acanya® Gel

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Benzoyl Peroxide
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents

ClinicalTrials.gov processed this record on September 30, 2014